= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
MSACL 2019 US : Clarke

MSACL 2019 US Abstract

Self-Classified Topic Area(s): Practical Training
Making the Switch: Issues & Challenges to Adopt Mass Spectrometry for Therapeutic Drug Monitoring (TDM)

William Clarke
Department of Pathology, Johns Hopkins Hospital


Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
 William Clarke (Presenter)
Johns Hopkins School of Medicine

Relevant Financial Disclosures (within past 24 months)
Grant/Research Support Thermo Fisher Scientific
Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above.
Conflict mitigation IN PROCESS.

Abstract

As more laboratories continue to bring up mass spectrometry-based tests, this session will discuss the issues and challenges faced during the adoption and switch to LC-MS/MS for therapeutic drug monitoring using clinical examples from the speaker’s laboratory.